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San Matteo and University of Pavia, Pavia, ItalyRecently released clinical practice guidelines and consensus Introduction
conference statements point to the importance of hepatitis B virus
(HBV) genotyping in therapeutic algorithms for the treatment of
chronic hepatitis B. This information usually comes from post
hoc analyses of clinical trials which were not designed to study
associations with the HBV genotype. We have performed a litera-
ture search through to April 2009 and have selected randomized
clinical trials of currently approved anti-HBV drugs providing
information on HBV genotypes and (i) baseline characteristics of
study subjects, (ii) any response to antiviral therapy, (iii) interac-
tion between HBV genotypes and the type of therapy. There were
several intrinsic features and weaknesses in the majority of clinical
trials conducted so far which make it difﬁcult to reach ﬁrm conclu-
sions about the role of HBV genotypes in response to antiviral ther-
apy. Indeed, most trials were necessarily multicenter in order to
reach a sufﬁcient statistical power, but pooling together patients
of different ethnicities may have revealed false-positive associa-
tions between response to antiviral therapy and HBV genotype.
Moreover, endpoint deﬁnitions, especially for the composite ones,
varied substantially among studies, leading to lack of homogene-
ity. Finally, possible interactions between the type of therapy
and the HBV genotype were only seldom analysed. The present
review highlights several caveats regarding current indications
proposed by the major clinical practice guidelines and consensus
conference statements published thus far and emphasise the need
for further long term studies in the ﬁeld.
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ferase; PCR, polymerase chain reaction.Hepatitis B virus (HBV) is responsible for a large number of chronic
infections worldwide and its control and eradication are considered
one of the major public health challenges of the 21st century [1].
Similarly to hepatitis C virus (HCV), HBV persistence and progres-
sion to chronic liverdiseaseare thought to result fromacombination
of viral and host factors [2]. The evolutionary history of major hepa-
titis viruses in different human populations includes the origin of
phylogenetic variants named genotypes. Several clinical and epide-
miological observations suggest that genetic differences in viral
genotypesmay underlie differences in biological and clinical behav-
iours. More importantly, although for HCV infections genotyping
has become an essential part of therapeutic algorithms [3], the evi-
dence that HBV genotypes play any role in response to antiviral
treatment is much less clear. The problem is further compounded
by the fact that drugswhich have exclusive antiviral activity against
HBV, such as nucleos(t)ide analogues (NUC’s), seem not to be inﬂu-
encedby genotypes,whereas interferon-adoes [4]. TheHBV-speciﬁc
antiviral pharmacopoeia is limited to NUC’swhich display a broader
genotypic coverage than the protease and non-nucleosidic inhibi-
tors of human immunodeﬁciency virus (HIV) and HCV; however,
the information provided in pivotal clinical trials is often incom-
plete. Here we shall review data on the therapeutic implications of
HBV genotypeswith the aim of discussing established tenets aswell
as controversial issues. Moreover, we shall brieﬂy discuss whether
the main characteristics of patients before starting treatment dif-
fered according to HBV genotypes.HBV genotype geographical distribution and relevant clinical
correlates
A genotype is a viral variant which sufﬁciently differs from other
variants of the same virus to constitute a distinct phylogenetic
group. This simple deﬁnition also implies that several virus isolates
worldwidewould fall in a particular genetic group to support single
anecdotal reports and that there is evidence for spread of a speciﬁc
genotype in particular transmission networks. In order to achieve
this distinction, evidence of infection with a speciﬁc viral genotype
should be provided in several independently infected individuals.
The identiﬁcation of newgenotypeswill henceforth require demon-
stration of a consistent independent genetic grouping. Until now,2010 vol. 52 j 441–449
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eight HBV genotypes have been identiﬁed and are numbered alpha-
betically from A to H [5]. HBV genotypes differ by at least 8% from
each other [6] and several subtypes (at least 24) have been
described, except for genotypes E and G [7]. Not unexpectedly,
HBV genotypes and subtypes show a distinct geographical distribu-
tion, with genotype A being typically isolated in Northern Europe
and countries with a strong prevalence of populations of Northern
European origin, including the USA, but is occasionally seen also in
the Indian subcontinent. Genotype D is highly prevalent in Eastern
Europe, the Mediterranean countries and the Middle East, whereas
genotypes B and C are typical of China and Japan. Infections with
genotypesE, F, G andHare rarer andusually observed inWestAfrica,
Central-South America, Central Europe and Southern USA, and Cen-
tral America, respectively [7]. Infection with more than one geno-
type is possible [8] and there is evidence that super-infection may
be accompanied by acute exacerbation of the underlying chronic
disease, suggesting that adaptive immunitymay not always be pro-
tective across genotypes [9]. Recombination among genotypes is
possible and it has been shown that recombination between geno-
types B and C has led to the generation of two different strains with
distinct geographic distribution [10]. A relationship between HBV
genotypes and clinical outcome of hepatitis B has been reported
but most studies have compared genotypes B and C or genotypes
D and A, because of their geographical distribution, indicating that
genotypes A and B are generally associated with a more benign
course of infection [1]. Indeed, there is evidence that cirrhosis and
HCC are more frequent in carriers of genotype C than B [11–13]
and a recent long-term prospective study on a large number of
HBV carriers from Taiwan showed that HBV genotype C was associ-
ated with an increased risk of hepatocellular carcinoma (HCC) [14].
While strong epidemiological and clinical data support clear clinical
differences between genotypes B and C, the evidence in favour of
genotype A being more benign than D is softer, and to determine
whether clinically signiﬁcant differences in the natural history are
true will require large longitudinal studies in European and North
American countries. Indeed, a study performed among Alaska
Natives suggested theopposite,with theoddsofHCCbeing4.7 times
greater in adults with genotype A (95% conﬁdence interval
(CI) = 1.4–16.0) and 11.7 times greater in adults with genotype F
(95% CI = 5.4–25.4) compared to those with genotype D [15]. More-
over, themolecular virological mechanisms that contribute to these
clinical differences among HBV genotypes are far from being
determined.Is antiviral treatment outcome inﬂuenced by viral genotype?
Treatment objectives in chronic HBV infection are to obtain hepa-
titis B e antigen (HBeAg) loss or anti-HBe seroconversion in
HBeAg-positive patients which is often associated with liver dis-
ease remission [1]. Although HBeAg-positive patients are com-
monly observed in Asia and Northern Europe, the typical
European or Mediterranean patient would be anti-HBe positive
and therefore other therapeutic endpoints should be considered.
Complete and sustained suppression of HBV replication, and
improvement in necroinﬂammatory activity and ﬁbrosis of the
liver, which are associated with delayed disease progression, are
valuable short-term end points [4,16]. Ideally, HBsAg and anti-
HBs seroconversion is now considered the objective closest to a
cure and can be observed in a respectable proportion of patients
after complete viral suppression is achieved and stable after treat-
ment discontinuation.442 Journal of Hepatology 20Genotype and interferon treatment
Largemulticenter trials of peginterferon (PEG-IFN)a showed that in
patients treated with PEG-IFN-a-2b there was a statistically signiﬁ-
cant association between viral genotype and sustained HBeAg loss.
Thus, when all interferon-treated patients were examined indepen-
dently of concomitant lamivudine treatment, the highest rate of
HBeAg clearance at the end of follow-up occurred in patients
infected with genotype A (47%), followed by genotype B (44%), C
(28%) and D (25%). Further analyses of the same study population
demonstrated that HBsAg clearance was also closely linked to viral
genotype, being highest in genotype A (14%) compared to B (9%), C
(3%) and D (2%) [17]. A re-evaluation of the data carried out approx-
imately 3 years later indicated that among patients who cleared
HBeAg in the initial study, 96% of those with genotype A were still
HBeAg-negative and 58% were HBsAg-negative, whereas the same
endpoints were achieved in 86% and 14% of patients with genotype
B, 67% and 0% of patients with genotype C and 76% and 6% of those
with genotype D, respectively [18]. These data indicate that durable
HBeAg loss after interferon therapy occurs most frequently in
patientswithgenotypesAandB, and this is associatedwitha greater
chance forHBsAg clearanceuponprolonged follow-up [17]. A recent
meta-analysis [19] and a pooled analysis of over 1200 patients [20]
provide compelling support for the fact that genotype A is the most
treatment-responsive genotype in HBeAg-positive hepatitis B.
Genotype A is relatively uncommon in HBeAg-negative cases, but
non-D genotypes, particularly C, appear to have higher rates of sus-
tained virological response in this form of chronic hepatitis B. The
reasons for the different rates of virological response according to
genotype remain unclear but may relate to changes in viral
sequences during interferon therapy that affect host immune
responses [21]. An alternative but rather speculative explanation
could be that different routes of HBV transmission, mostly horizon-
tal for genotype A vs vertical for other genotypes, could inﬂuence T-
cell reactivity to HBV proteinswhichmay explain the clinical obser-
vations of higher HBsAg loss during treatment of patients infected
with HBV genotype A with PEG-IFN. T-cell exhaustion following
exposure tohigh viral antigen concentration in the peripheral blood,
as it occurs for vertically transmitted genotypes,may be responsible
for inefﬁcient responses [22].Genotype and treatment with nucleos(t)ide analogues
Besides standard or pegylated interferon, current treatment
options include three nucleoside analogues [lamivudine (LAM),
telbivudine (LdT) and entecavir (ETV)], and two nucleotide ana-
logues [adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate
(TDF)]. A previous meta-analysis on both observational studies and
clinical trials published up to 2007 failed to detect a genotype
effect on treatment responses to analogues [19]. However, that
study did not take into account that different studies evaluated dif-
ferent endpoints and it did not include in the analysis continuous
responses such as ALT normalization and serum DNA level reduc-
tions. We have therefore reviewed the results from clinical trials
published up to 2009 with data on the association between HBV
genotypes and response to therapy, giving a more complete pic-
ture of all the study endpoints, in order to identify, if possible, a
single pattern of response to therapy according to HBV genotype.
Moreover, we have brieﬂy described the baseline characteristics
of HBV infected patients according to the HBV genotypes.10 vol. 52 j 441–449
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Literature search
We performed a literature search through to April 2009 on Pub-
Med using combinations of the keywords ‘‘HBV”, ‘‘genotype”,
‘‘treatment”, ‘‘pegylated interferon”, ‘‘lamivudine”, ‘‘adefovir”,
‘‘entecavir”, ‘‘telbivudine”, ‘‘tenofovir”, with no search restrictions.
We selected only randomised clinical trials with any information
provided on HBV genotypes and (i) baseline characteristics of
study subjects, (ii) any response to antiviral therapy and (iii) inter-
action with the type of therapy. In addition, we reviewed the ref-
erences from the retrieved articles and relevant reviews to identify
additional studies. Overall, we went through the full text of 32 arti-
cles from 20 different clinical trials. We excluded 17 papers that
did not report any useful information for analyses on HBV geno-
types. Fifteen papers from 13 different clinical trials were eventu-
ally included in this review.Data extraction and methods
For each study we recorded information on the publication year,
study location, period of accrual, weeks of treatment, patient age
range, type of therapy and doses, HBeAg-status, studied end-
point(s) and treatment endpoint(s) by HBV genotype.
We extracted any available information (including p-values)
from tables and text on the differences in baseline characteristics
and treatment endpoints by HBV genotype. For studies investi-
gating the interaction between HBV genotypes and type of ther-
apy, p-value for interaction was extracted and reported in our
database as well. Among the 15 reviewed papers, 11 reported
data for the analyses on HBV genotypes, while the remaining four
papers just stated in the text that at the multivariate analysis no
association with HBV genotype was found for the studied
endpoints.
For binary outcomes, when crude data were reported without
any p-value for the statistical analysis, we constructed the fre-
quency table and calculated the p-value for Chi-Square test. P-val-
ues <0.05 were considered statistically signiﬁcant, unless speciﬁed.
Chi-Square test was performed using SAS software, version 8.2
(SAS Institute, Inc., Cary, NC, USA).Baseline patient characteristics and HBV genotypes
Several trials reported the main patient characteristics before
starting antiviral therapy, according to HBV genotype (Table 1),
including HBeAg-status, serum HBV-DNA levels, presence of
advanced ﬁbrosis or cirrhosis, resistance to lamivudine and ALT
levels. Although one study did not provide p-values for the signif-
icance of differences in serum HBV-DNA and ALT levels among
HBV genotypes [17], evidence from other reports suggested that
all the investigated characteristics differed by HBV genotype.
Patients with genotype D were more frequently HBeAg-negative
compared to patients with other genotypes, while patients with
genotype C seemed to be less frequently HBeAg-negative. By pool-
ing frequencies from the four studies with available data [23–26],
134 out of 447 subjects with genotype A (30%) were HBeAg-nega-
tive, compared with 273/809 (34%) with genotype B, 355/1326
(27%) with genotype C and 648/917 (71%) with genotype D. Serum
HBV-DNA levels seemed higher among patients with genotypes D
and A, and lower in patients with genotypes C and B [17,27]. Prev-Journal of Hepatology 20alence of advanced ﬁbrosis or cirrhosis was higher among carriers
of genotypes A and C [26,28].Response to therapies with NUC’s and HBV genotypes
Results from studies which investigated the association between
HBV genotypes and response to therapy with NUC’s are presented
in Table 2.
Among HBeAg-positive patients, the investigated endpoints
were: HBeAg seroconversion, drug resistance, ALT normalization
and PCR negativity. None of these endpoints differed signiﬁcantly
among HBV genotypes either with univariate or multivariate anal-
ysis (p-values >0.10). Just one study [29] presented the percentage
of HBeAg seroconversion according to HBV genotype: it was
slightly higher in patients with genotypes A and B compared to
patients with genotypes C and D, although the association was
not statistically signiﬁcant.
Among HBeAg-negative patients, the investigated endpoints
were: drug resistance, ALT normalization and PCR negativity. The
GLOBE study [30] found a signiﬁcantly lower risk of LdT-resistance
in patients with genotype C compared to patients with genotypes
non-C at the univariate analysis. This association, however, disap-
peared after adjustment for potential confounders in multivariate
analysis. No other study reported any signiﬁcant association in this
group of patients.
Drug resistance, serum HBV-DNA level reductions, and PCR
negativity have been further cumulatively investigated on
HBeAg-positive and -negative patients: again, no signiﬁcant asso-
ciation with HBV genotypes was highlighted.Response to IFN-based therapies and HBV genotypes
Results from studies which investigated the association between
HBV genotypes and response to IFN-based therapies are presented
in Table 3.
Among HBeAg-positive patients, the investigated endpoints
were: HBeAg seroconversion, HBeAg loss, serum HBV-DNA level
reduction, PCR negativity, ALT normalization and composite end-
points. Differences in percentages of HBeAg seroconversion among
HBV genotypes have been found in one Chinese multicenter study
[31]: patients with genotype B had more often HBeAg seroconver-
sion than subjects with genotype C. In another multicenter study
[29], however, the percentage of subjects with HBeAg seroconver-
sion was similar between genotypes B and C, and slightly higher
for genotypes A than D, although the difference was not statisti-
cally signiﬁcant. Percentage of subjects with HBeAg loss signiﬁ-
cantly differed among genotypes in the two studies with
available data [17,32], with genotype A patients having higher
probability of HBeAg loss than genotypes C and D patients, and
genotype B patients having higher probability of HBeAg loss than
genotype C patients in one Chinese study [31]. This last result
was not conﬁrmed in another multicenter study [32]. In the same
Chinese study, patients with genotype B reported signiﬁcantly
higher serum HBV-DNA level reduction, higher rate of PCR negativ-
ity and ALT normalization than patients with genotype C. When
considering the composite endpoints (HBeAg seroconversion + PCR
negativity and HBeAg loss + PCR negativity + ALT normalization),
patients with genotypes A and B have been found to respond bet-
ter to therapy compared to genotypes C and D.10 vol. 52 j 441–449 443
Table 1. Baseline characteristics of patients and HBV genotypes.
Study name
(reference)
No. of patients HBeAg pos./neg. Baseline characteristic Baseline characteristic
by HBV genotype
Signiﬁcance
(p-valueo)
GLOBE
(Lai, 2007)
[23] 1370 Both Prevalence of HBeAg-
negative patients
A: 26 (32%) YES
(p < 0.0001*)B: 118 (33%)
C: 175 (25%)
D: 121 (56%)
Other/missing: 6 (35%)
–
(Hou, 2008)a
[24] 332 Both Prevalence of HBeAg-
negative patients
B: 10 (8%) YES
(p < 0.004*)C: 31 (15%)
102 and 103
(Marcellin, 2008)
[25] 641 Both Prevalence of HBeAg-
negative patients
A: 42 (42%) YES
(p < 0.0001*)B: 39 (53%)
C: 41 (37%)
D: 235 (73%)
Other/missing: 18 (51%)
AI463022 BEHoLD,
AI463027 BEHoLD,
AI463026 BEHoLD
(Schiff, 2008)
[26] 1633 Both Prevalence of HBeAg-
negative patients
A: 66 (25%) YES
(p < 0.0001*)B: 106 (42%)
C: 108 (35%)
D: 292 (77%)
F: 3 (9%)
Other/missing: 63 (55%)
GS-98-437
(Westland, 2003)
[27] 511 Positive Serum HBV-DNA levels
(log10 copies/ml)
A: 8.44 YES
(p < 0.0001)B: 8.25
C: 7.83
D: 8.47
E: 7.11
F: 7.66
G: 9.49
HBV 99-01
(Flink, 2006)
[17] 266 Positive Serum HBV-DNA levels
(log10 copies/ml)
A: 9.1 UNKNOWN
B: 8.3
C: 8.3
D: 9.5
GS-98-438
(Westland, 2003)
[27] 184 Negative Serum HBV-DNA levels
(log10 copies/ml)
A: 6.44 YES
(p = 0.0001)B: 6.51
C: 6.52
D: 7.16
E: 7.22
F: 6.83
HBV 99-01
(Buster, 2007)
[28] 239 Positive Prevalence of patients with
advanced ﬁbrosis
A: 38 (49%) YES
(p < 0.001)B: 4 (19%)
C: 10 (28%)
D: 15 (16%)
AI463022 BEHoLD,
AI463027 BEHoLD,
AI463026 BEHoLD
(Schiff, 2008)
[26] 1633 Both Prevalence of patients with
advanced ﬁbrosis or
cirrhosis
A: 42 (16%) YES
(p = 0.02*)B: 24 (10%)
C: 51 (17%)
D: 56 (15%)
F: 10 (29%)
Other/missing: 18 (16%)
AI463022 BEHoLD,
AI463027 BEHoLD,
AI463026 BEHoLD
(Schiff, 2008)
[26] 1633 Both Prevalence of Lamivudine
refractory patients
A: 69 (27%) YES
(p = 0.002*)B: 40 (16%)
C: 55 (18%)
D: 101 (27%)
F: 7 (20%)
Other/missing: 14 (12%)
HBV 99-01
(Flink, 2006)
[17] 266 Positive Baseline ALT ( ULN) A: 4.2 UNKNOWN
B: 4.2
C: 3.9
D: 4.6
a Study conducted in China.
o p-value for difference among genotypes.
* p-value was not presented in the original paper. We calculated it by reported data using the Chi-Square test.
ReviewAmong HBeAg-negative patients, one study [33] investigated
virological response and the composite endpoint virological
response + ALT normalization. The authors found a signiﬁcant
difference among HBV genotypes for both the investigated end-
points: patients with genotypes B and C had a better response to
therapy compared to patients with genotype D; patients with
genotypes A and D had a similar response to therapy. All in
all, preliminary conclusions can be drawn that while genotype
B appears to perform better than C in Chinese populations, the444 Journal of Hepatology 20data is insufﬁcient in non-Chinese populations. More individual
data linking genotype to ethnic background will need to become
available.Interaction between HBV genotype and antiviral therapy
Four studies tried to assess whether there was an interaction
between HBV genotypes and type of treatment in determining10 vol. 52 j 441–449
Table 2. Response to therapies with nucleos(t)ide analogues and HBV genotypes.
Study name
(reference)
Nucleos(t)ide/
control group
(no. of
patients)
Weeks of
treatment
Treatment endpoint Endpoint deﬁnition Treatment
endpoint by HBV
genotype
Signiﬁcance
(p-valueo)
HBeAg-positive patients
GS-98-437
(Westland, 2003)
[27] Adefovir/none
(511)
48 HBeAg seroconversion Loss of serum HBeAg and
appearance of anti-HBe
From 7% to 20%
among genotypes
A–D
NO
(p = 0.25)
Peginterferon Alfa-2a
HBeAg-Positive Chronic
Hepatitis B Study Group
(Lau, 2005)
[29] Lamivudine/
none (272)
48 HBeAg seroconversion Loss of serum HBeAg and
appearance of anti-HBe
antibody
A: 3 (20%)
B: 17 (23%)
C: 29 (18%)
D: 3 (18%)
NO
(p = 0.81*)
GLOBE
(Liaw, 2009)
[34] Telbivudine/
Lamivudine
(1367)
104 HBeAg seroconversion Not reported NO
(multivariate p > 0.10)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (458)
104 HBeAg seroconversion Not reported NO
(multivariate p > 0.10)
AI463026
BEHoLD
(Sherman, 2008)
[35] Entecavir/
Lamivudine
(286)
96 Drug resistance Virologic breakthrough
deﬁned as increased in HBV
DNA of P1 log10 in copies/
ml from the on-treatment
nadir, as determined by at
least two sequential
measurements or the last on-
treatment measurements
Not reported NO
(multivariate p not signiﬁcant)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (458)
104 Drug resistance Emergence of treatment-
associated resistance
mutations
NO
(multivariate p > 0.10)
GLOBE
(Liaw, 2009)
[34] Telbivudine/
Lamivudine
(1367)
104 ALT normalization Not reported NO
(multivariate p > 0.10)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (458)
104 ALT normalization Not reported NO
(multivariate p > 0.10)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (458)
104 PCR negativity Proportion of patients with
undetectable HBV DNA by
PCR assay (<300 copies/ml)
Not reported NO
(multivariate p > 0.10)
HBeAg-negative patients
GS-98-438
(Hadziyannis,
2006)
[36] Adefovir/
placebo (184)
240 Drug resistance Presence of adefovir-
resistance mutations (N236T
or A181V)
Not reported NO
(multivariate p > 0.10)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (222)
104 Drug resistance Emergence of treatment-
associated resistance
mutations
Not reported YES
OR = 0.17, p = 0.0099 for C
vs non-C (univariate analysis)
NO
at multivariate analysis
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (222)
104 ALT normalization Not reported NO
(multivariate p > 0.10)
GLOBE
(Zeuzem, 2009)
[30] Telbivudine/
none (222)
104 PCR negativity Proportion of patients with
undetectable HBV DNA by
PCR assay (<300 copies/ml)
Not reported NO
(multivariate p > 0.10)
Both HBeAg-positive and -negative patients
(Hou, 2008)a [24] Telbivudine/
Lamivudine
(332)
104 Drug resistance Viral breakthrough with
identiﬁed treatment-
emergent resistance mutations
B: 15 (12%)
C: 17 (8%)
NO
(multivariate p not signiﬁcant)
GLOBE
(Liaw, 2009)
[34] Telbivudine/
Lamivudine
(1367)
104 Drug resistance Viral breakthrough with the
emergence of treatment-
associated resistance
mutations
Not reported NO
(multivariate p > 0.10)
GS-98-437
GS-98-438
(Westland, 2003)
[27] Adefovir/
none (695)
48 Serum HBV-DNA levels
reduction (log10 copies/
ml)
Change between baseline
levels of serum HBV-DNA
and HBV-DNA levels after
48 weeks of therapy
A: 3.58
B: 3.42
C: 3.65
D: 3.68
E: 3.60
F: 4.23
G: 3.67
NO
(p = 0.90)
GLOBE
(Liaw, 2009)
[34] Telbivudine/
Lamivudine
(1367)
104 PCR negativity Proportion of patients with
undetectable HBV DNA by
PCR assay (<300 copies/ml)
Not reported NO
(multivariate p > 0.10)
OR, odds ratio.
*p-value was not presented in the original paper. We calculated it by reported data using the Chi-Square test.
a Study conducted in China.
o p-value for difference among genotypes.
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Table 3. Response to IFN-based therapies and HBV genotypes.
Study name
(reference)
IFN/control group
(no. of patients)
Months
of
treatment
Treatment endpoint Endpoint deﬁnition Treatment
endpoint by
HBV genotype
Signiﬁcance
(p-valueb)
HBeAg-positive patients
Peginterferon Alfa-2a [29] Pegylated IFN-a-2a/
Lamivudine (814)
48 weeks HBeAg seroconversion Loss of HBeAg and
appearance of
anti-HBe antibody
A: 19 (34%)
B: 64 (28%)
C: 122 (25%)
D: 7 (19%)
NO
(p = 0.37*)HbeAg-Positive Chronic
Hepatitis B Study Group
(Lau, 2005)
Peginterferon Alfa-2a [29] Pegylated IFN-a-2a/
none
(271)
48 weeks HBeAg seroconversion Loss of HBeAg and
appearance of
anti-HBe antibody
A: 12 (52%)
B: 23 (30%)
C: 50 (31%)
D: 2 (22%)
NO
(p = 0.18*)HbeAg-Positive Chronic
Hepatitis B Study Group
(Lau, 2005)
Peginterferon Alfa-2a [29] Pegylated IFN-a-2a/
+Lamivudine/none
(271)
48 weeks HBeAg seroconversion Loss of HBeAg and
appearance of
anti-HBe antibody
A: 4 (22%)
B: 24 (29%)
C: 43 (28%)
D: 2 (18%)
NO
(p = 0.84*)HbeAg-Positive Chronic
Hepatitis B Study Group
(Lau, 2005)
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
IFN-a-2b
(230)
24 weeks HBeAg seroconversion B: 33.3%
C: 12.9%
YES
(p = 0.0012)
HBV 99-01
(Janssen, 2005)
[32] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
+ Lamivudine (266)
52 weeks HBeAg loss Loss of serum
HBeAg, as tested by
EIA
A: 42 (47%)
B: 10 (44%)
C: 11 (28%)
D: 26 (25%)
YES
OR (95% CI) =
2.4 (1.3–4.6) for A vs D
3.6 (1.4–8.9) for A vs C
2.2 (0.7–7.0) for B vs C
HBV 99-01
(Flink, 2006)
[17] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
+ Lamivudine (266)
52 weeks HBsAg loss Loss of serum
HBsAg at the end of
follow-up
A: 13 (14%)
B: 2 (9%)
C: 1 (3%)
D: 2 (2%)
YES
(p for difference
between genotypes A
and D = 0.006)
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
IFN-a-2b (230)
24 weeks HBeAg loss B: 22 (36.7%)
C: 22 (12.9%)
YES
(p = 0.0004)
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
IFN-a-2b (230)
24 weeks Serum HBV-DNA
level reduction (log10
copies/ml)
Change between
baseline levels
of serum HBV-DNA
and HBV-DNA
levels after 48 weeks (24
therapy + 24 follow-up)
B: 2.23
C: 0.88
YES
(p < 0.0001)
HBV 99-01
(Buster, 2007)
[28] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
+ Lamivudine (239)
26 weeks HBeAg
seroconversion + serum
HBV DNA < 10,000
copies/ml
Loss of HBeAg and
appearance of
anti-HBe + serum HBV DNA
level < 10, 000 copies/ml
A: 23 (30%)
B: 5 (26%)
C: 1 (3%)
D: 6 (6%)
YES
RR (95% CI) =
11.3 (1.4–92.6) for A vs C
4.3 (1.4–13.2) for A vs D
12.1 (1.2–118.3) for B vs C
4.6 (1.1–18.4) for B vs D
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
(230)
24 weeks HBeAg loss + serum
HBV-DNA < 100,000
copies/ml + normal
ALT levels
B: 16 (31.7%)
C: 13 (7.7%)
YES
OR (95% CI) =
0.19 (0.08–0.46) for C vs B
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
(230)
24 weeks PCR negativity Serum HBV DNA
levels < 100,000
copies/ml
B: 28 (46.7%)
C: 28 (16.5%)
YES
(p < 0.0001)
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
(230)
24 weeks PCR negativity Serum HBV DNA
levels < 1,000
copies/ml
B: 17 (28.3%)
C: 11 (6.5%)
YES
(p < 0.0001)
–
(Zhao, 2007)a
[31] Pegylated IFN-a-2b/
Pegylated IFN-a-2b
(230)
24 weeks ALT normalization B: 34 (56.7%)
C: 45 (26.5%)
YES
(p = 0.0002)
HBeAg-negative patients
Peginterferon Alfa-2a
HbeAg-Negative Chronic
Hepatitis B Study Group
(Bonino, 2007)
[33] Pegylated IFN-a-2a/
Pegylated IFN-a-2a +
Lamivudine (294)
48 weeks Virological response HBV-DNA level
<20,000 copies/
ml at the end of treatment
and at
24 weeks post-treatment
A: 6 (35%)
B: 33 (45%)
C: 70 (62%)
D: 29 (33%)
YES
(multivariate
p = 0.006)
OR (95% CI) =
3.3 (1.7–6.5) for C vs D
Peginterferon Alfa - 2a
HbeAg-Negative Chronic
Hepatitis B Study Group
(Bonino, 2007)
[33] Pegylated IFN-a-2a/
Pegylated IFN-a-2a +
Lamivudine/
Lamivudine
(518)
48 weeks ALT normalization
+HBV DNA level of
<20,000 copies/ml
Not reported YES
(multivariate
p < 0.001)
OR (95% CI) =
0.42 (0.1–1.2) for A vs B
0.33 (0.1–0.9) for A vs C
0.97 (0.3–2.7) for A vs D
0.79 (0.5–1. 3) for B vs C
2.31 (1.3–4. 2) for B vs D
2.9 (1.7–5.0) for C vs D
Review
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Table 3 (continued)
Study name
(reference)
IFN/control group
(no. of patients)
Months
of
treatment
Treatment endpoint Endpoint deﬁnition Treatment
endpoint by
HBV genotype
Signiﬁcance
(p-valueb)
Peginterferon Alfa-2a
HbeAg-Negative
Chronic
Hepatitis B Study
Group
(Bonino, 2007)
[33] Pegylated IFN-a-2a/
Lamivudine
(346)
48 weeks ALT normalization
+HBV DNA level of
<20,000 copies/ml
B: 38 (41%)
C: 46 (38%)
D: 16 (14%)
YES
(multivariate
p < 0.001)
OR (95% CI) =
5.9 (2.7–13.1) for B vs D
4.6 (2.2–9.5) for C vs D
Peginterferon Alfa-2a
HbeAg-Negative
Chronic
Hepatitis B Study
Group
(Bonino, 2007)
[33] Pegylated IFN-a-2a/
Pegylated IFN-a-2a
+ Lamivudine
(304)
48 weeks ALT normalization
+ HBV DNA level of
<20,000 copies/ml
One year after
treatment
Not reported YES
OR (95% CI) =
2.58 (0.73–9.20) for A vs D
3.69 (1.54–8.79) for B vs D
5.46 (2.46–12.1) for C vs D
CI, conﬁdence intervals; OR, odds ratio; RR, relative risk.
a Study conducted in China.
b p-value for difference among genotypes.
* p-value was not presented in the original paper. We calculated it by reported data using the Chi-Square test.
JOURNAL OF HEPATOLOGYthe response to therapy. Studied endpoints included histological
improvement, PCR negativity, HBeAg seroconversion and compos-
ite endpoints.
Two [25,34] out of the four studies [25,31,33,34] focused on
response to therapy with NUC’s. In the ﬁrst one [25], histological
improvement was more common in patients treated with TDF than
in patients treated with ADV for all genotypes but B; for patients
with this latter genotype the difference in histological improve-
ment between the two treatments was 4.4% (95% CI: 26.3%;
17.5%); among the other genotypes, the highest difference
between the two treatments was observed for genotype C [8.1%
(9.1%; 25.3%)]. Similarly, in the same study the lower difference
between the two treatments (in favour of TDF) for PCR negativity
and for the combined endpoint PCR negativity + histological
improvement was observed for patients with genotype B, while
the highest difference between treatments was observed for
patients with genotype A. However, the p-value for interaction
between the HBV genotype and treatment was not statistically sig-
niﬁcant. The GLOBE study [34] compared LdT with LAM and found
that the HBeAg seroconversion rate was signiﬁcantly higher in
patients treated with LdT compared to patients treated with LAM
only for carriers of HBV genotype C (p = 0.03), while no difference
between the two treatments was found for the other genotypes.
Two studies on IFN-based therapies [31,33] evaluated differ-
ence in treatments according to HBV genotypes. The ﬁrst one
[33], which included HBeAg-negative patients, found a signiﬁcant
genotype-therapy interaction (p = 0.03): ALT normalization + PCR
negativity occurred more frequently after treatment with PEG-
IFN-a-2a plus LAM than after treatment with LAM alone in
patients with HBV genotype D (OR; 95% CI: 3.5; 1.3–9.1). The asso-
ciation was opposite in patients with genotype B (OR; 95% CI: 0.4;
0.1–1.2). In a further study comparing PEG vs standard IFN [31],
patients treated with standard IFN had a signiﬁcantly higher
response rate (HBeAg seroconversion + PCR negativity + ALT nor-
malization) than patients treated with PEG-IFN just among
patients with HBV genotype C (p = 0.02).Conclusive remarks
The present review discloses several intrinsic features and weak-
nesses of the clinical trials conducted so far which make it difﬁcultJournal of Hepatology 20to reach ﬁrm conclusions on the role of HBV genotypes in response
to antiviral therapy. First, HBV genotype distribution varied signif-
icantly among different populations. Indeed, almost all trials were
multicenter and pooled together patients of different ethnicities. If
for any reason differences in response to therapy depend on eth-
nicity, then a false-positive association with the HBV genotype
may be discovered since overlap between ethnicity and genotype
is very high. Adjusting by ethnicity in multivariate analysis may
lead to co-linearity. Stratiﬁed analysis by ethnic group may be a
solution, but it would signiﬁcantly lower the statistical power.
Large studies within the same geographical populations are
needed to clarify this point. Second, most studies did not provide
information on response to therapy by HBV genotype, especially
when no difference in treatment endpoints by genotype was pres-
ent. This precludes obtaining a pooled estimate of the association
between each endpoint and HBV genotype: it is indeed possible
that each study found no signiﬁcant association, but this might
be the result of their low statistical power, and combining them
in a meta-analysis of individual data may lead to a signiﬁcant
result. Third, endpoint deﬁnitions, especially for the composite
ones, varied substantially among studies, leading to lack of homo-
geneity. A consensus in endpoint deﬁnition would be highly desir-
able, at least within large multicenter clinical trials. Fourth,
possible interactions between the type of therapy and the HBV
genotype have seldom been analysed. Among the four studies
which gave a result, three reported a somewhat different response
to different therapies according to the HBV genotype. It is there-
fore possible that speciﬁc treatments may be more effective on
some HBV genotypes and not on others. This should be further
investigated in future studies, possibly within ongoing large mul-
ticenter clinical trials. This last point is extremely important as
most clinical trials are still running at the time of this review, even
though the follow-up for some of them is limited to subgroups of
patients and therefore conclusions may presently be premature.
Nevertheless, current evidencedoes suggest that potentially bet-
ter responders to PEG-IFN a treatment can be identiﬁed by HBV
genotyping; although patients with ‘‘unfavourable” genotypes
should not be denied treatmentwith IFN, as theymay have a beneﬁt
in the long term by achieving a durable anti-HBs seroconversion
[37]. Besides this consideration, the present analysis highlights sev-
eral caveats regarding current indications put forward by the major
clinical practice guidelines and consensus development conference10 vol. 52 j 441–449 447
Review
statements published thus far, and emphasise the need for further
long term investigations into this matter.Key messages
 There are at least eight HBV genotypes which are
geographically distributed.
 Genotype A and B may be associated with a more benign
clinical course than D and C but these data may be biased by
ethnicity.
 Genotype A and B may respond to IFN-based therapies better
than C and D, while NUC therapy does not appear to be
inﬂuenced by genotype.
 The above statement is limited by several caveats:
– Ethnicity and genotype may overlap.
– Clinical trials were not designed to analyse response by
genotype.
– Variability of endpoint deﬁnitions.
– Interaction between type of therapy and genotype.Acknowledgements
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